The Cooper Companies Powers Through Q2 2026 with Record Revenue and Non-GAAP Earnings
The Cooper Companies has delivered a stellar performance in the second quarter of 2026, with record revenue and non-GAAP earnings per share. According to Albert White, President and Chief Executive Officer, the company achieved revenues of $1.08 billion, an impressive 8% increase over the same period last year. Non-GAAP earnings per share also rose by 26%, marking the tenth consecutive quarter where the company has beaten consensus earnings expectations.
CooperVision reported a solid quarter, with revenues increasing 8%, or 4% organically, driven by continued strength in the Americas and momentum in EMEA. CooperSurgical also performed well, with revenues up 8%, or 6% organically, led by the fertility business growing 13%, or 10% organically.
One of the key highlights of the quarter was the meaningful operating margin expansion achieved by both CooperVision and CooperSurgical. This was largely due to back-office consolidation and efficiency initiatives, which continued to deliver operating leverage, especially within CooperSurgical.
The company's strategic review is also gaining momentum, with settlements now reached with substantially all claimants related to a December 2023 embryo culture media recall in the fertility business. As disclosed in the Form 8-K filed with the earnings release, this has allowed the company to actively advance discussions with multiple parties that have submitted significant indications of interest in CooperSurgical.
According to White, the company has received robust interest in CooperSurgical, and is working with speed to identify the optimal path forward to maximize shareholder value. The strong performance of CooperSurgical this past quarter has strengthened confidence in the business, and underscores its view that it is a very valuable asset.
The company's capital allocation strategy remains focused on investing in high-return organic growth opportunities, maintaining balance sheet flexibility, and repurchasing shares. With another quarter of robust free cash flow generated, confidence in the strength and durability of the company's cash generation has been reinforced.
CooperVision's continued strength in the Americas and momentum in EMEA, combined with CooperSurgical's solid performance, have both contributed to the company's overall success. The company's commitment to innovation, new product introductions, and generating free cash flow continues to drive sustainable and profitable growth.
The company's results reflect steady execution against its strategy, which has been demonstrated through its ability to deliver record revenue and non-GAAP earnings per share. With a solid foundation in place, the company is poised for continued success in the future.
